What is the recommended dose of Uremol HC (sodium polystyrene sulfonate) for a patient with hyperkalemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Uremol HC Dosing

Uremol HC is dosed as one tablet orally 4 times per day, followed by liberal fluid intake in adults. 1

Adult Dosing

  • Standard dose: 1 tablet orally 4 times daily 1
  • Must be followed by liberal fluid intake to ensure adequate hydration 1

Pediatric Dosing

  • Dosage must be individualized by a physician for older children 1
  • Not recommended for children 6 years of age or younger 1

Important Clarification

The evidence provided appears to contain a labeling discrepancy. The user question asks about "Uremol HC" with context suggesting sodium polystyrene sulfonate (Kayexalate) for hyperkalemia, but the FDA label 1 describes "Urelle®," which is actually a urinary analgesic/antiseptic combination product, not a potassium binder. These are completely different medications with different indications.

If the question is actually about sodium polystyrene sulfonate (Kayexalate) for hyperkalemia:

Kayexalate Dosing for Hyperkalemia

  • Oral: 15-30 g orally, typically given 1-4 times daily 2, 3, 4
  • Rectal: 30-50 g as retention enema 2
  • The practical exchange ratio is approximately 1 mEq potassium per 1 gram of resin 2
  • Studies show 30 g daily can reduce serum potassium by 1.04 mEq/L more than placebo over 7 days 2, 4

Critical Safety Warnings for Kayexalate

  • Should NOT be used as emergency treatment for life-threatening hyperkalemia due to delayed onset of action 2
  • Concomitant administration with sorbitol is not recommended due to risk of intestinal necrosis 2
  • Serious gastrointestinal adverse events including intestinal necrosis have been reported 2
  • Contains 100 mg (4.3 mmol) sodium per 100 g powder, which may be problematic in patients with hypertension or fluid overload 2

References

Guideline

Kayexalate Dosing for Hyperkalemia Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD.

Clinical journal of the American Society of Nephrology : CJASN, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.